288 results on '"Kiefer, James"'
Search Results
2. Preclinical development of ZED8, an 89Zr immuno-PET reagent for monitoring tumor CD8 status in patients undergoing cancer immunotherapy
3. Discovery of Potent, Selective, and Orally Available IRE1α Inhibitors Demonstrating Comparable PD Modulation to IRE1 Knockdown in a Multiple Myeloma Model
4. A BCMA/CD16A bispecific innate cell engager for the treatment of multiple myeloma
5. Discovery of GNE-6893, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of HPK1.
6. Trastuzumab does not bind rat or mouse ErbB2/neu: implications for selection of non-clinical safety models for trastuzumab-based therapeutics
7. A lexical semantic hub for heteromodal naming in middle fusiform gyrus.
8. Correction to: Preclinical development of ZED8, an 89Zr immuno‑PET reagent for monitoring tumor CD8 status in patients undergoing cancer immunotherapy
9. Utilizing hydrogen exchange measurements to drive small molecules into cryptic protein binding sites
10. Water molecules in protein–ligand interfaces. Evaluation of software tools and SAR comparison
11. Uncovering the functional anatomy of the human insula during speech
12. Structural basis for dual-mode inhibition of the ABC transporter MsbA
13. Post-translational regulation of RORγt—A therapeutic target for the modulation of interleukin-17-mediated responses in autoimmune diseases
14. Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3Kα
15. Correction to: Preclinical development of ZED8, an 89Zr immuno‑PET reagent for monitoring tumor CD8 status in patients undergoing cancer immunotherapy
16. Development of an 18F-labeled anti-human CD8 VHH for same-day immunoPET imaging
17. Preclinical development of ZED8, an 89Zr immuno-PET reagent for monitoring tumor CD8 status in patients undergoing cancer immunotherapy
18. Development of an 18F-labeled anti-human CD8 VHH for same-day immunoPET imaging.
19. Target 2035 – update on the quest for a probe for every protein
20. The critical role of the ventral temporal lobe in word retrieval
21. Preclinical development of ZED8, an 89Zr immuno-PET reagent for monitoring tumor CD8 status in patients undergoing cancer immunotherapy.
22. Discovery of GNE-502 as an orally bioavailable and potent degrader for estrogen receptor positive breast cancer
23. Trastuzumab does not bind rat or mouse ErbB2/neu: implications for selection of non-clinical safety models for trastuzumab-based therapeutics
24. On the Validity of the Kirkwood-Riseman Theory
25. A Truncated Test for Choosing the Better of Two Binomial Populations
26. GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer
27. Discovery of a C-8 hydroxychromene as a potent degrader of estrogen receptor alpha with improved rat oral exposure over GDC-0927
28. Unexpected equivalent potency of a constrained chromene enantiomeric pair rationalized by co-crystal structures in complex with estrogen receptor alpha
29. Structure analysis reveals the flexibility of the ADAMTS-5 active site
30. Stereochemical Differences in Fluorocyclopropyl Amides Enable Tuning of Btk Inhibition and Off-Target Activity
31. The kinase IRAK4 promotes endosomal TLR and immune complex signaling in B cells and plasmacytoid dendritic cells
32. Discovery of GNE-149 as a Full Antagonist and Efficient Degrader of Estrogen Receptor alpha for ER+ Breast Cancer
33. Structural insights into the stereochemistry of the cyclooxygenase reaction
34. Uncovering the functional anatomy of the human insula during speech
35. Author response: Uncovering the functional anatomy of the human insula during speech
36. Discovery of Potent Benzolactam IRAK4 Inhibitors with Robust in Vivo Activity
37. Visualizing DNA replication in a catalytically active Bacillus, DNA polymerase crystal
38. Observing Translesion Synthesis of an Aromatic Amine DNA Adduct by a High-fidelity DNA Polymerase
39. Truncated Version of a Play-the-Winner Rule for Choosing the Better of Two Binomial Populations
40. Some properties of the a+b → C reaction-diffusion system with initially separated components
41. Development of Potent and Selective Pyrazolopyrimidine IRAK4 Inhibitors
42. Fluorescent indomethacin-dansyl conjugates utilize the membrane-binding domain of cyclooxygenase-2 to block the opening to the active site
43. Target 2035 – update on the quest for a probe for every protein
44. Inhibition of bromodomain-containing protein 9 for the prevention of epigenetically-defined drug resistance
45. From a novel HTS hit to potent, selective, and orally bioavailable KDM5 inhibitors
46. Recent developments in electronic banking: the rapid expansion of the use of the debit card.
47. Design and evaluation of 1,7-naphthyridones as novel KDM5 inhibitors
48. Lead optimization of a pyrazolo[1,5-a]pyrimidin-7(4H)-one scaffold to identify potent, selective and orally bioavailable KDM5 inhibitors suitable for in vivo biological studies
49. Discovery of 3-Cyano-N-(3-(1-isobutyrylpiperidin-4-yl)-1-methyl-4-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)benzamide: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor C2 Inverse Agonist
50. Structural basis for antagonism of bacterial LPS transport
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.